With the applications of magnetic resonance imaging (MRI) at higher magnetic fields increasing, there is demand for MRI contrast agents with improved relaxivity at higher magnetic fields. Macromolecule-based contrast agents, such as protein-based ones, are known to yield significantly higher r 1 relaxivity at low fields, but tend to lose this merit when used as T 1 contrast agents (r 1 / r 2 = 0.5 ~ 1), with their r 1 decreasing and r 2 increasing as magnetic field strength increases. Here, we developed and characterized an in vivo applicable magnetic resonance ( With the applications of MRI in higher magnetic fields (> 7 T) both in preclinical and clinical settings increasing, there are needs to develop MRI contrast agents with improved relaxivity at higher magnetic fields. From MRI perspective, the advantage of higher magnetic field is attractive, as it is expected to drastically increase signal to noise ratio (SNR) and resolution 1, 2 . However, it is generally observed that spin-lattice time (T 1 ) increases and converges for different tissues as the magnetic field strength increases, which reduces contrast for T 1 -weighted exams using the same imaging parameters used at conventional 1.5 or 3 T 3, 4 . As contrast to noise ratio (CNR) is critical for the sensitivity and specificity of MRI exams, this reduction of inherent T 1 contrast necessitates the development of efficient in vivo compatible positive contrast agent with good relaxivity characteristics at higher magnetic field [5] [6] [7] [8] . Protein cage nanoparticles, including ferritins, encapsulins, and virus-like particles (VLPs), have been widely used as nanoscale delivery vehicles for diagnostic and/or therapeutic reagents 9-21 as they not only have well-defined structure and size, but also consist of biocompatible and biodegradable biomaterials, polypeptides 22 . The highly symmetrical and uniformly composed architecture of protein cage nanoparticles allow them to be manipulated in a highly controlled manner, resulting in the production of reproducible nanoscale multifunctional particles [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . VLPs have been extensively studied as supramolecular templates for the conjugation of small molecule contrast agents, such as the chelated paramagnetic
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) with an acceptable r 1 /r 2 ratio (0.5 ~ 1) at high magnetic field (7 T), are a rarity 8, [31] [32] [33] [34] . In the present study, we used lumazine synthase, isolated from the hyperthermophile Aquifex aeolicus (AaLS), as a nanoscaled template for T 1 contrast conjugates as illustrated in Fig. 1A and evaluated its potential as an in vivo MR contrast agent at the magnetic field strength of 7 T. AaLS is composed of 60 identical subunits that form an icosahedral capsid architecture (T = 1 state) with respective exterior and interior diameters of 15.4 nm and 9 nm 35 . AaLS is known to catalyze the penultimate step of riboflavin biosynthesis within cells 36 . The structural robustness and functional plasticity of AaLS make it an attractive candidate for a versatile bio-and nanotechnological platform [37] [38] [39] [40] [41] [42] [43] [44] . Its hollow spherical architectures have been used as templates for the encapsulation of functional proteins 37, [43] [44] [45] [46] and the biomimetic synthesis of iron oxides 44 , as well as delivery vehicles of therapeutic and/or diagnostic reagents 32, 34 . AaLS has also been engineered into multifunctional building blocks for fabricating uniform layer-by-layer (LbL) assemblies using non-covalent interactions between surface-displayed hexahistidine and Ni-NTA of AaLS 39 . For our application, Gd(III)-chelating agent complexes were attached at position 108 with cysteine (R108C), which is known to be exposed on the exterior surface of AaLS.
Experimentally, Gd(III)-DOTA-AaLS were characterized by mass spectroscopy (MS) to ensure that AaLS was modified with only one Gd(III)-DOTA complex per subunit. Transmission emission microscopy (TEM) was used subsequently to ensure that the cage architecture and stoichiometry of AaLS is not significantly altered in the Gd complex conjugation. Next, r 1 and r 2 MR relaxivities were measured at 1.4 T and 7 T with multiple Gd concentration phantoms. In vivo imaging experiments were performed at the magnetic field strength of 7 T using a tumor bearing mouse, before and after the injection of Gd(III)-DOTA-AaLS-R108C. Observed signal behaviors were directly compared with the corresponding results from the injection of conventional Gd-DOTA (DOTAREM) for both vasculature and tumor regions. 
Materials and Methods
Gd(III)-DOTA-AaLS-R108C as MRI contrast agent (MRI CA). AaLS does not have sufficiently large inter-subunit spaces for Gd(III)-chelating agent complexes to freely diffuse into its interior cavity. Thus, to attach Gd(III)-chelating agent complexes in a site-specific and number controlled manner, we substituted the arginine residue at position 108 with cysteine (R108C), which is known to be exposed on the exterior surface of AaLS and readily to be used as a site for the attachment of small molecules [47] [48] [49] . To fully saturate the chelating agents (maleimido-monoamide-DOTA (DOTA-mal)) with Gd(III), they were incubated with an excess of Gd(III) prior to conjugation to AaLS. Subsequently, AaLS was treated with 3 mol equivalents of Gd(III)-DOTA-mal for attachment at room temperature with vigorous shaking overnight (Fig. 1A) . Unreacted Gd(III)-DOTA-mal were removed by extensive dialysis with multiple changes of buffer. The extent of the conjugation was determined by subunit mass measurements using electrospray ionization time-of-flight mass spectrometry (ESI-TOF; Xevo G2 TOF).
Cell and animal models. Squamous Relaxivity Measurements. We measured the T 1 and T 2 relaxation times of the Gd(III)-DOTA-AaLS under 1.4 T (Bruker Minispec MQ60 TD-NMR, 60 MHz) and 7 T (Bruker BioSpec 70/16 US, 300 MHz) magnets. At 60 MHz, the T 1 relaxation times of the Gd(III)-DOTA-AaLS were measured using the inversion recovery (IR) method with the IR delay ranging from 0-20000 ms. T 2 relaxation times were measured with a CPMG sequence with echo spacing (TE) of 1 ms and recycling time (TR) of 1.5 s. At 300 MHz, the T 1 relaxation time was estimated using a sequence of rapid acquisition with relaxation enhancement (RARE) at variable repetition times; 10 TR values of 20-5000 ms were used with echo time (TE) of 7.6 ms. The T 2 relaxation time was measured using a multi-slice multi-echo (MSME) method at TR of 5000 ms with 50 TE values in the range of 20-1000 ms. The proton relaxivities (r 1 : longitudinal relaxivity and r 2 : transverse relaxivity) were determined by measuring the T 1 relaxation times and T 2 relaxation times of six different Gd concentrations of Gd(III)-DOTA-AaLS-R108C (0.074, 0.037, 0.0185, 0.00925, 0.004625, and 0 mM). Both relaxivities r 1 and r 2 were calculated from the slope of the relaxation rate R 1 (1/T 1 ) and R 2 (1/T 2 ) as a function of concentration (mM) of contrast agent, respectively. We previously demonstrated that the relaxivities of protein cage nanoparticles conjugated with Gd(III)-chelating agent can be determined by measuring the T 1 relaxation time and corresponding Gd(III) concentrations 23 . The relaxivities of Gd(III)-DOTA-AaLS-R108C were calculated using the linear relaxivity equation used in a previous study 23, 26 . The proton relaxivities of saline solutions with untreated AaLS-R108C at identical concentrations were determined, as AaLS may also give T 1 enhancement as well.
In vivo imaging of tumor-bearing mice. All tumor-bearing mice weighing 20-25 g (tumor volume: ~100 mm 3 ) were scanned using 7 T MRI (Bruker Biospec) with a transceiver RF volume coil (diameter: 40 mm) for the mouse body, maintained under anesthesia with 1.0-1.5% isoflurane. Radiofrequency power and receiver adjustments were continuously maintained for each scan. Four mice were examined to investigate the vasculature imaging capabilities and the tumor accumulation efficacy of Gd(III)-DOTA-AaLS-R108C at high field (7 T) and two mice in the control group were assessed using Gd-DOTA (DOTAREM) as a reference. Four mice were injected intravenously with 350 μ l of Gd(III)-DOTA-AaLS-R108C (concentration: 17.143 mM) as a bolus into the tail vein. Also in the same manner, two mice were injected intravenously with 350 μ l of DOTAREM (concentration: 17.857 mM) as a bolus into the tail vein for the direct comparisons.
For the longitudinal and direct comparison of the vasculature imaging capability and delivery efficacy of Gd(III)-DOTA-AaLS-R108C to the tumor region, three dimensional (3D) MR angiography (MRA) and T 1 -mapping were adopted at six time points (1, 2, 3, 7, 12 , and 30 h) after the intravenous injection of the contrast agent at a dose of 0.3 mmol/kg. To this end, a 3D-Fast Low-Angle Shot (FLASH) and a RARE with variable repetition time TR (RAREVTR) sequence were used for a high-resolution angiogram and T 1 -map, respectively. MR parameters were set as follows: TR = 13 ms, TE = 2. 
of 27413.6 and 28096.9 Da and only one mass peak was observed (Fig. 1B) . Mass spectrometric data indicated that all subunits of AaLS-R108C were modified with only one Gd(III)-DOTA complex (60 Gd(III)-DOTA per cage). The Gd-content of Gd(III)− DOTA conjugated AaLS-R108C was independently measured with inductively coupled plasma-mass spectrometry (ICP-MS) and the Gd-content was determined to be 0.86 Gd(III) per subunit, which is slightly lower than the value determined by MS probably due to slight sample loss during ICP-MS sample preparation 23 . To avoid overestimation of the relaxivity of Gd(III)-DOTA-conjugated AaLS-R108C (Gd(III)-DOTA-AaLS-R108C), we used the Gd content as determined by MS 23 . Gd(III)-DOTA-AaLS-R108C was eluted at the same position as untreated AaLS-R108C in size exclusion chromatography (Fig. 1C) and transmission electron microscopic images of negatively stained Gd(III)-DOTA-AaLS-R108C showed its intact cage architecture with the same size as untreated AaLS (~15 nm in diameter, Fig. 1D ). Zeta potential measurements revealed that Gd(III)-DOTA-AaLS-R108C had slightly lower negative surface charge (− 8.2 mV) than that of AaLS-R108C (− 5.5 mV) probably due to the introduced Gd(III)-DOTA. These results demonstrate that Gd(III)-DOTA-mal conjugation to AaLS-R108C does not significantly alter its cage architecture or stoichiometry.
Relaxivity measurements with phantoms. The T 1 relaxation times became shorter under both 1.4 T and 7 T, as the Gd(III) concentrations increased ( Fig. 2A-1,C-1) suggesting that the Gd(III)-DOTA-AaLS-R108C supramolecular template accelerated the recovery of net magnetization. Corresponding T 2 relaxation times also decreased as Gd(III) concentrations increased ( Fig. 2A-2 ,C-2). Gd(III)-DOTA-AaLS-R108C showed higher T 1 relaxivity (r 1 = 30.24 mM , Fig. 2C-3 ) under high magnetic field (7 T, room temp.), the measured r 1 /r 2 values of Gd(III)-DOTA-AaLS-R108C were 0.73 and 0.52 for 1.4 T and 7 T, respectively, indicating that Gd(III)-DOTA-AaLS-R108C remains as the optimal T 1 contrast agent at 7 T 23, 26 . The T 1 and T 2 relaxation times measurements with increasing concentration of untreated AaLS-R108C at identical experimental conditions were shown in Fig. 2B-1 , r 2 = 3.14 mM
, Fig. 2D-3 ) were determined as reference.
To evaluate the potential usage of Gd(III)-DOTA-AaLS-R108C as an in vivo T 1 contrast agent at high magnetic field, we captured T 1 -weighted MR images of the phantom using a volume coil with a 7 T MRI scanner using a RAREVTR sequence at 4 TR values (100, 500, 1000, and 2000 ms). T 1 -weighted in vitro phantom images of PBS control (S1A), AaLS-R108C only (S1B) and Gd(III)-DOTA-AaLS-R108C with increasing concentrations (S1C) were shown in supporting Fig. 1 . While the MR signal intensities of Gd(III)-DOTA-AaLS-R108C were significantly enhanced at short TRs (500 and 1000 ms), those of the PBS control and AaLS-R108C were not, as shown in supporting Figure S1C , S1A, and S1B, respectively. As the Gd concentration of Gd(III)-DOTA-AaLS-R108C is increased, the accelerated R 1 values of Gd(III)-DOTA-AaLS-R108C led to contrast enhancement resulting in brighter images at short TRs as shown in Figure S1C . For the comparisons with conventional DOTAREM, saturation recovery signals with RAREVTR at multiple TR values were plotted together, where the Gd concentrations (0.0185, 0.037, and 0.074 mM) were kept same for both Gd(III)-DOTA-AaLS-R108C and DOTAREM as shown in S1D. Increased R 1 values were apparent for Gd(III)-DOTA-AaLS-R108C at the same concentration, which led to enhanced r 1 relaxivity over conventional DOTAREM at 7 T.
In vivo characterizations. 3D MR angiograms and T 1 maps of tumor-bearing mice were generated to evaluate both the feasibility of MR angiography and the tumor accumulation efficacy using newly developed Gd(III)-DOTA-AaLS-R108C. Identical experiments and analysis were repeated with conventional DOTAREM for direct comparisons. From these MR data, region of interest (ROI) analysis was also employed to measure regionally averaged T 1 values and corresponding signal enhancement.
The decreasing trend in T 1 values of the tumor region of mice was consistently observed after the time point of ~7 h post-Gd(III)-DOTA-AaLS-R108C injection. Figure S2A and S2B illustrates this, showing T 1 maps before and 30 h after the injection. Supplementary Figure S2C shows the corresponding T 1 fitting results at both time points, respectively. Decreased T 1 values in the tumor region could clearly be observed 30 h after the injection of Gd(III)-DOTA-AaLS-R108C both with T 1 maps and corresponding raw T 1 fitting results.
MIP images of tumor bearing mice taken at sequential time points (pre, post, 2 h, 7 h, 12 h, and 30 h) after the injection of Gd(III)-DOTA-AaLS-R108C were plotted in the first column of Fig. 3A . Immediately after the injection, blood vessels were brightened as the T 1 values in the vessels significantly decreased due to the contrast agent injection. As time progressed, positive contrast in blood vessel diminished and ~7 h after the injection, the positive contrast in the tumor region started to appear. T 1 shortening of tumor regions was further confirmed by T 1 maps shown in the second column of Fig. 3B and the median-shift of the T 1 histogram distribution of the whole 3D tumor volume, shown in the third column of Fig. 3C . Identical analysis was performed with conventional DOTAREM as shown in Fig. 3D-F . Blood vessels were also brightened right after the injection and dimming. Positive T 1 contrast in the tumor region was apparent up to 2 h after the injection of DOTAREM, and positive T 1 contrast diminished and the T 1 values were restored to original values 7 h post-injection. Longitudinal maximum intensity projection (MIP) images before and after the injections of Gd(III)-DOTA-AaLS-R108C (n = 4) and DOTAREM (n = 2) were shown in supporting Figure S3 . Figure 4A ,B present ROI analysis, showing the temporal trend of signal enhancement measured in the arterial region after injection with Gd(III)-DOTA-AaLS-R108C and conventional DOTAREM. The signal enhancement trend in artery caused by both agents had a similar pattern. Directly after injection, maximal arterial signal enhancements were obtained from both contrast agents, this enhancement diminished as time progressed. A slower decreasing slope of arterial signal enhancement with Gd(III)-DOTA-AaLS-R108C than that from conventional DOTAREM was observed presumably from the elongated intravascular residence time of Gd(III)-DOTA-AaLS-R108C due to its size and hydrophilic surface. No meaningful arterial signal enhancements were observed 7 h and 30 h after injection with DOTAREM and Gd(III)-DOTA-AaLS-R108C, respectively.
Temporal variations of T 1 values in both tumor and muscle on the other side of flank after injection with Gd(III)-DOTA-AaLS-R108C and DOTAREM were presented in Fig. 4C ,D. For Gd(III)-DOTA-AaLS-R108C, the T 1 value in the tumor slowly decreased in the first 2 h post-injection, and started to show a statistically significant change from 7 h post-injection (p < 0.05), while T 1 in muscle showed no significant change at any time point. For DOTAREM on the other hand, the T 1 value in the tumor reached the minimum value at the initial time point right after the injection, and then rapidly rebounded and returned to its original level at 7 h. T 1 in muscle showed a similar trend to T 1 in tumor, with relatively reduced changes of T 1 values at each time point. 
Conclusions and Discussions
The high T 1 relaxivity of Gd(III)-DOTA-AaLS-R108C may result from the slow tumbling rate of its large cage architecture 28 . Most previous studies performed with VLPs and protein complexes as supramolecular conjugates haven shown relaxivities of 10-50 mM
, depending on experimental conditions [23] [24] [25] [26] [27] . When compared with experiments of Gd(III)-DOTA chelating agent conjugates we have performed previously, our measured value at 1.4 T (30.24 mM
) was slightly lower than that of large VLPs, P22 K118C WB (35.8 mM
), but slightly higher than small sized ferritin (19.9 mM
. The T 1 enhancement ability (r 1 /r 2 ) tends to decrease significantly as the magnetic field is increased and often represents a major problem when applying macromolecular contrast agents at high field. The measured r 1 /r 2 ratio (0.52) of Gd(III)-DOTA-AaLS-R108C at high magnetic field makes it attractive as a T 1 contrast agent at 7 T. It appears that the molecular hindrance mechanism and resulting dynamics of Gd(III)-chelating agent complexes conjugated to lumazine synthase determine overall relaxation characteristics, but the exact explanation is unresolved at this point. Future relaxation simulation may shed more light on these experimental observations.
In vivo MIP images after the injection of Gd(III)-DOTA-AaLS-R108C show clearly defined vasculature, as shown in Fig. 3A . Compared with Gd-DOTA, which exhibited fast leakage in a rodent model of vasculature imaging, intravascular Gd(III)-DOTA-AaLS-R108C appears to provide robust MR angiography at 7 T. The temporal trend of signal enhancement in the arterial region shows that optimal signal enhancement of the vasculature is achieved within 2 h of intravenous injection of Gd(III)-DOTA-AaLS-R108C.
As the longitudinal relaxation rate (R 1 ) in tumor is generally known to be proportional to Gd(III) concentration, the absolute T 1 (1/R 1 ) map of tumor and muscle regions on the other hind leg enables the monitoring of temporal variations in Gd(III) accumulation of both regions, with minimized animal repositioning and slice mismatch errors occurring in longitudinal follow up studies. In other words, decreasing absolute T 1 values in tissue should reflect increasing Gd(III) concentration of corresponding region. The T 1 value of the tumor decreased after the injected Gd(III)-DOTA-AaLS-R108C gradually migrated to the tumor region. A statistically significant decline in T 1 value was observed 7 h post-injection, which coincides with a significant drop in signal enhancement in the arterial region. Compared to the short retention time (< 2 h) of DOTAREM, due to its relatively small size and low molecular weight 45 , Gd(III)-DOTA-AaLS-R108C showed a prolonged retention time in tumor. A consistent T 1 value in the other hind leg muscle away from the tumor supported the tumor-specific migration of Gd(III)-DOTA-AaLS-R108C, presumably due to the enhanced permeability and retention effects of the tumor 46, 50 . These observations could be considered as the results of the abnormal characteristics of tumor tissue. In general, it is known that tumor tissues exhibit leaky vasculature and ineffective lymphatic drainage due to rapid and defective angiogenesis 51 . Hence, the tumor vasculature easily permits adequately sized macromolecules in plasma to escape from the tumor vessels and accumulate in tumor tissue for a specific time 50, 52 . Meanwhile, although the long retention time of Gd(III)-DOTA-AaLS-R108C in tumor could be a strength in applications relating to anti-tumor therapy or drug delivery, it may raise toxicity concerns due to the release of free Gd(III) from prolonged retention, and further in vivo toxicity study should be followed.
This study demonstrates that newly developed Gd(III)-DOTA-AaLS-R108C could be successfully applied as a positive T 1 MR contrast agent at high field, and utilized as a high-resolution vasculature imaging agent, active within 2 h of injection. Its prolonged retention time in tumors may be a key advantage for a potential theranostic nanoplatform, as well as for future scientific investigations of optimized MRI T 1 contrast agent at higher magnetic field.
